{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T21:31:08Z","timestamp":1774128668863,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00277-018-3412-8","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T12:07:30Z","timestamp":1530014850000},"page":"2081-2088","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database"],"prefix":"10.1007","volume":"97","author":[{"given":"Isao","family":"Fujioka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6493-6225","authenticated-orcid":false,"given":"Tomoiku","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihide","family":"Tokuhira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei-Ji","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Asou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"issue":"10","key":"3412_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ, Investigators I (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376(10):917\u2013927. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"issue":"5","key":"3412_CR2","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5):1044\u20131054. \n                    https:\/\/doi.org\/10.1038\/leu.2016.5","journal-title":"Leukemia"},{"issue":"6","key":"3412_CR3","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12185-017-2208-2","volume":"105","author":"H Nakamae","year":"2017","unstructured":"Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Ohashi K, Li L, Miyoshi M (2017) Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol 105(6):792\u2013804. \n                    https:\/\/doi.org\/10.1007\/s12185-017-2208-2","journal-title":"Int J Hematol"},{"key":"3412_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12185-017-2353-7","volume":"107","author":"H Nakamae","year":"2017","unstructured":"Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H (2017) Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol 107:327\u2013336. \n                    https:\/\/doi.org\/10.1007\/s12185-017-2353-7","journal-title":"Int J Hematol"},{"issue":"20","key":"3412_CR5","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A (2016) Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 34(20):2333\u20132340. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"issue":"8","key":"3412_CR6","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30(8):1648\u20131671. \n                    https:\/\/doi.org\/10.1038\/leu.2016.104","journal-title":"Leukemia"},{"issue":"7","key":"3412_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, Valent P (2011) Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 86(7):533\u2013539. \n                    https:\/\/doi.org\/10.1002\/ajh.22037","journal-title":"Am J Hematol"},{"issue":"5","key":"3412_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","volume":"12","author":"A Quintas-Cardama","year":"2012","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J (2012) Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 12(5):337\u2013340. \n                    https:\/\/doi.org\/10.1016\/j.clml.2012.04.005","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3412_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","volume":"2","author":"J Douxfils","year":"2016","unstructured":"Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogne JM (2016) Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol 2:625. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2015.5932","journal-title":"JAMA Oncol"},{"issue":"6","key":"3412_CR10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2015","unstructured":"Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P (2015) Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood 125(6):901\u2013906. \n                    https:\/\/doi.org\/10.1182\/blood-2014-09-594432","journal-title":"Blood"},{"issue":"6","key":"3412_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884. \n                    https:\/\/doi.org\/10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"issue":"13","key":"3412_CR12","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, European Association for Cardiovascular P, Rehabilitation, Guidelines ESCCfP (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33(13):1635\u20131701. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehs092","journal-title":"Eur Heart J"},{"issue":"18","key":"3412_CR13","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","volume":"97","author":"PW Wilson","year":"1998","unstructured":"Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837\u20131847","journal-title":"Circulation"},{"issue":"8","key":"3412_CR14","doi-asserted-by":"publisher","first-page":"784","DOI":"10.5551\/jat.19356","volume":"21","author":"K Nishimura","year":"2014","unstructured":"Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, Kokubo Y, Okayama A, Miyamoto Y (2014) Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the Framingham risk score: the Suita study. J Atheroscler Thromb 21(8):784\u2013798","journal-title":"J Atheroscler Thromb"},{"issue":"3","key":"3412_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. \n                    https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"3412_CR16","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/aje\/kwn064","volume":"167","author":"N Rumana","year":"2008","unstructured":"Rumana N, Kita Y, Turin TC, Murakami Y, Sugihara H, Morita Y, Tomioka N, Okayama A, Nakamura Y, Abbott RD, Ueshima H (2008) Trend of increase in the incidence of acute myocardial infarction in a Japanese population: Takashima AMI Registry, 1990-2001. Am J Epidemiol 167(11):1358\u20131364. \n                    https:\/\/doi.org\/10.1093\/aje\/kwn064","journal-title":"Am J Epidemiol"},{"issue":"9","key":"3412_CR17","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1161\/STROKEAHA.110.581033","volume":"41","author":"TC Turin","year":"2010","unstructured":"Turin TC, Kita Y, Rumana N, Nakamura Y, Takashima N, Ichikawa M, Sugihara H, Morita Y, Hirose K, Okayama A, Miura K, Ueshima H (2010) Ischemic stroke subtypes in a Japanese population: Takashima Stroke Registry, 1988-2004. Stroke 41(9):1871\u20131876. \n                    https:\/\/doi.org\/10.1161\/STROKEAHA.110.581033","journal-title":"Stroke"},{"issue":"3","key":"3412_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/M15-2306","volume":"165","author":"T Dahlen","year":"2016","unstructured":"Dahlen T, Edgren G, Lambe M, Hoglund M, Bjorkholm M, Sandin F, Sjalander A, Richter J, Olsson-Stromberg U, Ohm L, Back M, Stenke L, Swedish CMLG, the Swedish CMLRG (2016) Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med 165(3):161\u2013166. \n                    https:\/\/doi.org\/10.7326\/M15-2306","journal-title":"Ann Intern Med"},{"issue":"2","key":"3412_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12185-017-2225-1","volume":"106","author":"KJ Suh","year":"2017","unstructured":"Suh KJ, Lee JY, Shin DY, Koh Y, Bang SM, Yoon SS, Park S, Kim I, Lee JO (2017) Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. Int J Hematol 106(2):229\u2013239. \n                    https:\/\/doi.org\/10.1007\/s12185-017-2225-1","journal-title":"Int J Hematol"},{"issue":"5","key":"3412_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.clml.2016.01.006","volume":"16","author":"K Lang","year":"2016","unstructured":"Lang K, McGarry LJ, Huang H, Dorer D, Kaufman E, Knopf K (2016) Mortality and vascular events among elderly patients with chronic myeloid leukemia: a retrospective analysis of linked SEER-Medicare data. Clin Lymphoma Myeloma Leuk 16(5):275\u2013285 e271. \n                    https:\/\/doi.org\/10.1016\/j.clml.2016.01.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"3412_CR21","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/leu.2015.352","volume":"30","author":"PD Coutre le","year":"2016","unstructured":"le Coutre PD, Hughes TP, Mahon FX, Kim DW, Steegmann JL, Shah NP, Gooden K, Wallis N, Cortes JE (2016) Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia 30(7):1593\u20131596. \n                    https:\/\/doi.org\/10.1038\/leu.2015.352","journal-title":"Leukemia"},{"issue":"6","key":"3412_CR22","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, Levato L, Giles FJ, Dombret H, Mirault T, Labussiere H, Lindhorst R, Haverkamp W, Buschmann I, Dorken B, le Coutre PD (2013) Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27(6):1316\u20131321. \n                    https:\/\/doi.org\/10.1038\/leu.2013.70","journal-title":"Leukemia"},{"issue":"35","key":"3412_CR23","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M (2015) Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 33(35):4210\u20134218. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.62.4718","journal-title":"J Clin Oncol"},{"key":"3412_CR24","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/leu.2017.245","volume":"31","author":"E Hadzijusufovic","year":"2017","unstructured":"Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P (2017) Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia 31:2388\u20132397. \n                    https:\/\/doi.org\/10.1038\/leu.2017.245","journal-title":"Leukemia"},{"key":"3412_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.leukres.2017.05.005","volume":"58","author":"M Sukegawa","year":"2017","unstructured":"Sukegawa M, Wang X, Nishioka C, Pan B, Xu K, Ohkawara H, Hamasaki Y, Mita M, Nakamura K, Okamoto M, Shimura H, Ohta M, Ikezoe T (2017) The BCR\/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1beta in vascular endothelium in association with downregulation of miR-3p. Leuk Res 58:83\u201390. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2017.05.005","journal-title":"Leuk Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3412-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3412-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3412-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T19:13:57Z","timestamp":1561490037000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3412-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3412"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3412-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"25 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the research ethics boards of each institution participating in the study and was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Author Tomoiku Takaku has received a speaker honorarium from Bristol-Myers Squibb, Novartis Pharma K.K, Pfizer Inc. Noriyoshi Iriyama has received a speaker honorarium from Bristol-Myers Squibb. Michihide Tokuhira has received a speaker honorarium from Bristol-Myers Squibb and Pfizer Inc. Tatsuya Kawaguchi has received a speaker honorarium from Novartis Pharma K.K.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}